Drug manufacturers participating in the Section 340B Drug Pricing Program now face a significant new litigation risk under ...

In a bipartisan spending agreement that was largely negotiated behind closed doors, Congress included a policy change with ...

Illinois is facing an intense battle over a federal program requiring drug manufacturers to sell deeply discounted ...

The closer we get to 2028, the more likely it is that the U.S. may settle for short-term solutions that do not meaningfully ...

If New York legislators have questions about the efficacy of the 340B Drug Pricing Program, they should look closely at a ...

Kansas legislators, Republican and Democrat, are frustrated bills to help control prescription drug prices are blocked by GOP ...

The drug discount program is under scrutiny on a variety of fronts ...

A new state-by-state analysis released today by HEAL Collaborative provides further insight into how hospitals participating in the 340B program are allocating resources. The study, titled "The 340B ...

A federal court recently blocked the Trump administration from moving forward with a proposed pilot program that could have ...

HRSA is piloting a 340B rebate model similar to one that it just fought against. As the agency dips its toes into the 340B debate, hospital groups express concerns about the potential for cash flow ...

Drug companies are more likely than hospitals to violate 340B regulations, according to a recent American Hospital Association report. The 340B Drug Pricing Program has been under constant attack on ...

The 340B Drug Pricing Program was created to help a targeted group of safety net providers care for low-income and uninsured patients. First enacted as part of the Veterans Healthcare Act of 1992, ...